JP2018508567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508567A5 JP2018508567A5 JP2017555423A JP2017555423A JP2018508567A5 JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5 JP 2017555423 A JP2017555423 A JP 2017555423A JP 2017555423 A JP2017555423 A JP 2017555423A JP 2018508567 A5 JP2018508567 A5 JP 2018508567A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- sequence encoding
- nucleotide sequence
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 239000002773 nucleotide Substances 0.000 claims 19
- 125000003729 nucleotide group Chemical group 0.000 claims 19
- 239000013603 viral vector Substances 0.000 claims 16
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 13
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 10
- 102100034256 Mucin-1 Human genes 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000008088 immune pathway Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101710185679 CD276 antigen Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101150029662 E1 gene Proteins 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 101150066038 E4 gene Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 claims 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 1
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000008350 antigen-specific antibody response Effects 0.000 claims 1
- FUHMZYWBSHTEDZ-UHFFFAOYSA-M bispyribac-sodium Chemical compound [Na+].COC1=CC(OC)=NC(OC=2C(=C(OC=3N=C(OC)C=C(OC)N=3)C=CC=2)C([O-])=O)=N1 FUHMZYWBSHTEDZ-UHFFFAOYSA-M 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101969P | 2015-01-09 | 2015-01-09 | |
| US62/101,969 | 2015-01-09 | ||
| US201562150236P | 2015-04-20 | 2015-04-20 | |
| US62/150,236 | 2015-04-20 | ||
| PCT/US2016/012496 WO2016112195A1 (en) | 2015-01-09 | 2016-01-07 | Methods and compositions for combination immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508567A JP2018508567A (ja) | 2018-03-29 |
| JP2018508567A5 true JP2018508567A5 (enExample) | 2019-02-14 |
| JP6647315B2 JP6647315B2 (ja) | 2020-02-14 |
Family
ID=56356431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555423A Active JP6647315B2 (ja) | 2015-01-09 | 2016-01-07 | 組み合わせ免疫療法のための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11352642B2 (enExample) |
| EP (1) | EP3242940B1 (enExample) |
| JP (1) | JP6647315B2 (enExample) |
| KR (1) | KR102193635B1 (enExample) |
| CN (2) | CN113456812B (enExample) |
| AU (1) | AU2016205215B2 (enExample) |
| CA (1) | CA2974237C (enExample) |
| IL (1) | IL253341B (enExample) |
| WO (1) | WO2016112195A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP3256140B1 (en) | 2015-01-09 | 2020-04-01 | Etubics Corporation | Compositions for ebola virus vaccination |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| KR20190033483A (ko) * | 2016-06-03 | 2019-03-29 | 이투빅스 코포레이션 | 인간 파필로마바이러스 (hpv)-연관 질환의 치료를 위한 조성물 및 방법 |
| CN109843323B (zh) * | 2016-07-15 | 2022-06-07 | 埃特彼塞斯公司 | 用于黄病毒疫苗接种的组合物和方法 |
| JP6903120B2 (ja) | 2016-07-15 | 2021-07-14 | エトゥビクス コーポレーション | アルファウイルスワクチン接種のための組成物及び方法 |
| US11422127B2 (en) | 2016-12-07 | 2022-08-23 | Albany Medical College | Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens |
| WO2018186924A1 (en) * | 2017-01-17 | 2018-10-11 | The University Of Chicago | Dysfunctional antigen-specific cd8+ t cells in the tumor microenvironment |
| EP3630168A4 (en) * | 2017-05-26 | 2020-07-01 | Etubics Corporation | COMBINED IMMUNOTHERAPIES USING IL-15 SUPERAGONISTS |
| SG11202000197PA (en) * | 2017-07-11 | 2020-02-27 | Pfizer | Immunogenic compositions comprising cea muc1 and tert |
| CN118256563A (zh) | 2017-11-10 | 2024-06-28 | 北京卡替医疗技术有限公司 | 一种扩增免疫细胞的方法 |
| CN111836639A (zh) * | 2018-01-26 | 2020-10-27 | 河谷细胞有限公司 | 用于联合癌症疫苗和免疫辅助疗法的组合物和方法 |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| EP3773710A4 (en) * | 2018-04-04 | 2022-03-16 | Altimmune Inc | COMBINATIONS OF VACCINE COMPOSITIONS INDUCING T LYMPHOCYTES AND THEIR USES |
| JP2022500378A (ja) * | 2018-09-10 | 2022-01-04 | バーグ エルエルシー | ユビキチン結合酵素ｅ２ｋ（ｕｂｅ２ｋ）を阻害することによる癌の治療法 |
| EP4582440A3 (en) * | 2018-12-21 | 2025-10-08 | The Regents of the University of California | Il-10-containing vaccines and uses thereof |
| CN115066499A (zh) * | 2019-12-30 | 2022-09-16 | 格雷菲克斯公司 | 用于基因转移载体的高效产生的培养系统 |
| KR102371663B1 (ko) * | 2020-01-21 | 2022-03-04 | 코오롱생명과학 주식회사 | 아데노바이러스 벡터 |
| CN116059339B (zh) * | 2021-11-04 | 2023-09-22 | 元本(珠海横琴)生物科技有限公司 | 一种治疗和预防癌症的药物和应用 |
| CN117110607B (zh) * | 2023-09-16 | 2024-01-26 | 鲁东大学 | 一种检测副溶血性弧菌的组合物及其应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US820079A (en) | 1903-07-15 | 1906-05-08 | Auto Manual Piano Action Company | Musical instrument. |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| DE69312487T2 (de) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| WO1999008713A1 (en) | 1997-08-13 | 1999-02-25 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| ES2286530T3 (es) | 1997-10-10 | 2007-12-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos antagonistas del antigeno carcinoembrionario (cea). |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| EP1447414B1 (en) | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| EP1137792B9 (en) | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| US7009042B1 (en) | 1999-10-07 | 2006-03-07 | Corixa Corporation | Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins |
| WO2001030382A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| AU2001280674A1 (en) | 2000-07-20 | 2002-02-05 | Genstar Therapeutics Corporation | Mini-adenoviral vector system for vaccination |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US20040091995A1 (en) | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| JP2004535816A (ja) | 2001-07-20 | 2004-12-02 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物 |
| US8236776B2 (en) | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| ES2290449T3 (es) | 2002-04-09 | 2008-02-16 | Sanofi Pasteur Limited | Acido nucleico de cea modificado y vectores de expresion. |
| WO2004110345A2 (en) | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| JP2007523610A (ja) | 2003-05-05 | 2007-08-23 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 癌胎児抗原をコードする合成遺伝子およびその使用 |
| US8207314B2 (en) | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| JP4772674B2 (ja) | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途 |
| JP2007535304A (ja) | 2003-11-24 | 2007-12-06 | シドニー キンメル キャンサー センター | ムチン抗原ワクチン |
| CA2548347A1 (en) * | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| ES2616337T3 (es) | 2003-12-12 | 2017-06-12 | Government Of The United States Of America, As Repr. By The Secr. Of The Dept. Of Health And Human Services And His Successors | Un epítopo de linfocito T citotóxico humano y su epítopo agonista del número no variable de secuencias de repetición en tándem de MUC-1 |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| CA2555013C (en) | 2004-02-11 | 2013-10-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Carcinoembryonic antigen fusions and uses thereof |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US9592284B2 (en) | 2004-04-28 | 2017-03-14 | The Trustees Of The University Of Pennsylvania | Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost |
| KR101131727B1 (ko) | 2004-06-11 | 2012-03-28 | 가톨릭대학교 산학협력단 | ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물 |
| AU2005295317B2 (en) | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070249043A1 (en) | 2005-12-12 | 2007-10-25 | Mayall Timothy P | Adenoviral expression vectors |
| EP2013229A2 (en) | 2006-04-21 | 2009-01-14 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| WO2009015841A1 (en) | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| EP2419126B1 (en) * | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US20150182621A1 (en) | 2009-04-28 | 2015-07-02 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| JP2013522302A (ja) | 2010-03-14 | 2013-06-13 | グローブイミューン，インコーポレイテッド | 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 |
| AU2011226992B2 (en) | 2010-05-10 | 2012-03-22 | Ascend Biopharmaceuticals Pty Ltd | Immunostimulatory and vaccine compositions |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| AU2012228937B2 (en) | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
| RU2017143985A (ru) * | 2011-08-17 | 2019-02-14 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
| SG10201913795TA (en) | 2012-02-02 | 2020-03-30 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
| CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
| EP2864792A1 (en) | 2012-06-26 | 2015-04-29 | Biodesix, Inc. | Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies |
| GB201214007D0 (en) | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| EP2895191B1 (en) | 2012-09-14 | 2019-06-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Brachyury protein, adenoviral vectors encoding brachyury protein, and their use |
| KR20140100417A (ko) | 2013-02-05 | 2014-08-14 | 닛토덴코 가부시키가이샤 | 경피 투여용 백신 조성물 |
| CA3205348A1 (en) * | 2013-10-23 | 2015-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| EP4070818A3 (en) | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| WO2015104656A1 (en) * | 2014-01-07 | 2015-07-16 | Babita Agrawal | Immunomodulatory compositions and methods of use thereof |
| WO2015123532A1 (en) | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| WO2015127027A1 (en) | 2014-02-20 | 2015-08-27 | Wayne State University | Her2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| KR102409372B1 (ko) | 2014-04-11 | 2022-06-16 | 글로브이뮨 | 효모 면역 요법 및 타입 i 인터페론 감도 |
| EP3160498B1 (en) | 2014-06-30 | 2021-10-06 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| JP6647315B2 (ja) | 2015-01-09 | 2020-02-14 | イーチュービクス コーポレイション | 組み合わせ免疫療法のための方法および組成物 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2016
- 2016-01-07 JP JP2017555423A patent/JP6647315B2/ja active Active
- 2016-01-07 KR KR1020177022200A patent/KR102193635B1/ko active Active
- 2016-01-07 EP EP16735415.8A patent/EP3242940B1/en active Active
- 2016-01-07 CA CA2974237A patent/CA2974237C/en active Active
- 2016-01-07 AU AU2016205215A patent/AU2016205215B2/en active Active
- 2016-01-07 US US15/542,005 patent/US11352642B2/en active Active
- 2016-01-07 CN CN202110784166.7A patent/CN113456812B/zh active Active
- 2016-01-07 WO PCT/US2016/012496 patent/WO2016112195A1/en not_active Ceased
- 2016-01-07 CN CN201680014846.8A patent/CN107406857B/zh active Active
-
2017
- 2017-07-05 IL IL253341A patent/IL253341B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508567A5 (enExample) | ||
| Shaw et al. | Immunology of adenoviral vectors in cancer therapy | |
| Evans et al. | Immune suppression and colorectal cancer | |
| Kurooka et al. | Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells | |
| Van der Jeught et al. | Targeting the tumor microenvironment to enhance antitumor immune responses | |
| Li et al. | Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | |
| Dammeijer et al. | Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors | |
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| JP2018502922A5 (enExample) | ||
| WO2017210579A1 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| JP2018509163A5 (enExample) | ||
| Gildener-Leapman et al. | Tailored immunotherapy for HPV positive head and neck squamous cell cancer | |
| JP2019508044A5 (enExample) | ||
| Cervera-Carrascon et al. | Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. | |
| Biegert et al. | Current development in adenoviral vectors for cancer immunotherapy | |
| WO2017100338A4 (en) | Improved compositions and methods for viral delivery of neoepitopes and uses thereof | |
| Kitagawa et al. | An oral cancer vaccine using a Bifidobacterium vector suppresses tumor growth in a syngeneic mouse bladder cancer model | |
| Hughes et al. | Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma | |
| Zhao et al. | Enhanced antitumor immunity is elicited by adenovirus-mediated gene transfer of CCL21 and IL-15 in murine colon carcinomas | |
| Ge et al. | Emerging therapeutic strategies of different immunotherapy approaches combined with PD-1/PD-L1 blockade in cervical cancer | |
| Han et al. | AAV–sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo | |
| Moeini et al. | Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine | |
| Hernandez et al. | Fueling cancer vaccines to improve T cell-mediated antitumor immunity | |
| Long et al. | HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice | |
| Danishmalik et al. | Therapeutic tumor control of HER2 DNA vaccines is achieved by an alteration of tumor cells and tumor microenvironment by gemcitabine and anti-Gr-1 Ab treatment in a HER2-expressing tumor model |